News Headlines

1. LOTTE Biologics Expands Antibody Manufacturing Agreement With Ottimo Pharma 5/18/2026

   LOTTE Biologics (Co-CEOs James Park and Yooyeol Shin) announce an expansion of its collaboration with Ottimo Pharma, an innovative biotech company developing one-of-a-kind PD-1/VEGFR2 dual-paratopic antibodies, reinforcing a growing strategic partnership.

2. Aldevron And Minaris Renew Lentiviral Plasmid Agreement 5/14/2026

   FARGO, N.D. & PHILADELPHIA–(BUSINESS WIRE)–Aldevron, a Danaher company and global leader in the production of DNA, RNA and protein for genomic medicine, and Minaris, a global cell and gene therapy contract development and manufacturing organization (CDMO) and multimodality biosafety testing provider today announced a renewed licensing agreement that expands access to a proprietary, off-the-shelf lentiviral plasmid system for gene-modified cell therapy applications.

3. Charles River Laboratories And MEDIPOST Sign Non-Exclusive MOU To Advance GMP Testing Solutions 5/13/2026

   Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing, as well as broader commercial and marketing efforts to advance cell therapy development and commercialization.

4. Nuvation Bio To Collaborate With Thermo Fisher Scientific For U.S.-Based Manufacturing Of IBTROZI® For ROS1-Positive Non-Small Cell Lung Cancer 5/13/2026

   Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced the successful completion of process tech transfer and product introduction to Thermo Fisher Scientific, the world leader in serving science, for IBTROZI® (taletrectinib) to treat advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC).

5. Terumo Blood And Cell Technologies And Steminent Collaborate To Advance MSC Late-Stage Clinical Manufacturing 5/13/2026

   Terumo Blood and Cell Technologies (Terumo BCT), a medical technology company and global leader in blood management solutions, and Steminent Biotherapeutics have entered into a strategic collaboration to accelerate late-stage manufacturing readiness for mesenchymal stem cell (MSC) therapies, addressing one of the key barriers to clinical scale-up and commercialization in regenerative medicine.

6. Piramal Pharma Solutions Unveils State-Of-The-Art Payload-Linker Suite At Its Riverview, Michigan Facility 5/13/2026

   Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd.(“PPS”), has officially unveiled a new, state-of-the-art payload-linker development and manufacturing suite at its Riverview, Michigan drug substance facility.

7. Catalent And Elpida Therapeutics Enter Strategic Partnership For Late-Phase AAV Manufacturing 5/13/2026

   Elpida Therapeutics, a non-profit biotechnology company developing gene therapies for ultra-rare diseases, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced a strategic partnership to support late-phase manufacturing of Elpida’s lead program, an AAV9 gene therapy for Spastic Paraplegia Type 50 (SPG50).

8. OrganaBio Acquires Excellos Operating Assets, Establishing A Coast-To-Coast Cell Therapy Contract Testing, Development And Manufacturing Organization 5/13/2026

   OrganaBio, LLC ("OrganaBio"), a manufacturer of GMP cells and blood products and provider of cell isolation and cryopreservation services, has acquired substantially all of the operating assets of San Diego-based Excellos Inc. to create a bicoastal cell therapy contract development and manufacturing organization.

9. Fosun Pharma And Aribio Sign Exclusive Global Option Agreement For AR1001 For The Treatment Of Alzheimer's Disease 5/13/2026

   On 13 May, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"; stock code: 600196.SH, 02196.HK) and AriBio Co., Ltd. ("AriBio"), a biopharmaceutical company focused on neurodegenerative diseases, today jointly announced the signing of an exclusive global option agreement for the development, registration, manufacturing and commercialization of AR1001, an innovative drug candidate for the treatment of Alzheimer's disease (AD).

10. Andelyn Biosciences Receives Dark Horse Consulting Certification Of Gene Therapy Manufacturing Systems And Capabilities Within Its Initiative For Certification Of Manufacturing Capabilities (ICMC™) Program 5/13/2026

    Andelyn Biosciences, a leading cell and gene therapy Contract Development and Manufacturing Organization (CDMO), today announced it has received full certification under the Initiative for Certification of Manufacturing Capabilities (ICMC) program from Dark Horse Consulting, recognizing the company's capability to support advanced therapies manufacturing with its quality and production systems.